After disappointing trial results for cancer treatments, Mural Oncology announced Wednesday it is cutting 90% of its workforce.

After a lengthy regulatory back-and-forth, Eisai and Biogen's Alzheimer's drug is on the market in Europe. Elsewhere, Sarepta will start testing a new gene therapy for limb-girdle muscular dystrophy.

Mural Oncology stock skyrockets after it begins exploring strategic alternatives to maximize shareholder value after the failure of two cancer studies for nemvaleukin alfa.

Mural Oncology is halting development of its lead IL-2 therapy and enacting major layoffs after its second trial failure this ...

US biotech Mural Oncology has halted all development of its lead candidate, nemvaleukin alfa, after the engineered cytokine ...

Shares of Mural Oncology plc (NASDAQ: MURA) are soaring Monday following the company's announcement that it will discontinue clinical development of its lead drug candidate Nemvaleukin and begin ...

Mural Oncology plc said on Tuesday it would stop clinical development of its lead cancer treatment, nemvaleukin, and look ...

Real-time index price for TSX 60 Index (TXSX), along with buy or sell indicators, analysis, charts, historical performance, ...

April 15, 2025 (Investorideas.com Newswire) Investorideas.com ( www.investorideas.com ), a go-to platform for big investing ideas for stock traders, including biotech stocks reports on trading and ...

Boston and Dublin biotech Mural Oncology is laying off nearly all of its employees and ending clinical development of its IL-2 drug nemvaleukin alfa.

The writing is on the wall at Mural Oncology. Responding to clinical data, the biotech is laying off 90% of its employees and ...

Mural on Tuesday said it is ending all clinical development of its proposed nemvaleukin alfa cancer treatment and focusing on maximizing shareholder value. The Dublin-based company said it plans to ...